



## Clinical Epidemiology Center (CIC-EC); Leader

### Personal Information

Name: Geneviève Chêne  
 Data of birth: August 26<sup>th</sup>, 1962

Contact details: Centre d'investigation Clinique-Epidémiologie Clinique (CIC-EC)  
 Bâtiment ISPED  
 Université de Bordeaux  
 146 rue Léo Saignat  
 33076 Bordeaux cedex  
[genevieve.chene@isped.u-bordeaux2.fr](mailto:genevieve.chene@isped.u-bordeaux2.fr)  
 Tel: +33 05 57 57 12 57  
 Fax: +33 05 56 90 11 72

### Bio-sketch

Geneviève Chêne holds a Medical Degree and a PhD in clinical epidemiology, after training in Biostatistics at University "Paris-Sud" and at the London School of Hygiene and Tropical Medicine.

As a researcher, Geneviève has established an Inserm research team on "HIV infections and associated morbidity" and a Clinical Trials Unit as a platform of excellence for national and international studies in HIV/AIDS sponsored by the National Agency for Research on AIDS and viral hepatitis (ANRS). Most cited works show how the efficacy and safety of antiretroviral therapy can be durable over the long term (H=53, source WOS, May 2015). Since 2010, as principal co-investigator of Memento, a national cohort of 2,300 participants recruited in memory clinics and funded by the Presidential Plan 2008-2012, she is actively transferring know-how in other areas than HIV.

As a professor of public health, Geneviève teaches clinical epidemiology at the Bordeaux School of Public Health (Univ Bordeaux) where she initiated an international e-learning program in 2001.

In 2013, she was nominated in the "Comité des Sages" by the Prime Minister for the preparation of the National Strategy for Health. She has served as a peer reviewer for many scientific conferences and journals, and, until 2014, as academic editor for Plos ONE. Her main areas of interest are: Translational epidemiology and public health, clinical epidemiology, e-learning, infectious diseases, Alzheimer and neuro-degenerative diseases.

Geneviève Chêne is currently the Director of the Public Health Multi-Organization Thematic Institute of the French National Alliance for Life Sciences and Health (Aviesan and Inserm, Paris) and, since 2013, serves as vice-chair of the scientific evaluation committee of the National Program for Clinical Research (PHRC).

### Education

| YEAR(s) | INSTITUTION AND LOCATION                       | DEGREE               |
|---------|--|----------------------|
| 1990    | University Bordeaux                            | MD                   |
| 1990    | University Paris Sud                           | DEA (MSc equivalent) |
| 1993-94 | London School of Hygiene and Tropical Medicine | Research Fellow      |
| 1996    | University Bordeaux                            | PhD                  |
| 1998    | University Bordeaux                            | Habilitation         |

### Current Position

Since 1999 Professor of biostatistics and Public Health, University Bordeaux, CHU Bordeaux  
 Since 2007 Leader of the Inserm research team: "HIV and associated morbidities" (Inserm U897)  
 Since 2008 Leader of the Inserm Clinical Epidemiology Center (CIC-EC7)  
 Since 2011 Head, Department of Public Health ('Pole de Santé Publique'), Bordeaux University Hospital

### Other occupations

Since 2014 Director of the National Institute for Research in Public Health (Inserm/Aviesan)  
 Since 2014 Director of the "Institut de Recherche en Santé Publique" (Inserm and 22 other partners at the national level, including research institutions, agencies for health surveillance, medical insurances, and relevant directorates at ministries of health and research)

Scientific and Editorial Boards

|           |  |
|-----------|--|
| 2003      | Member of grant review committee applications submitted to the National Institute of Health for continuation of the Multicenter AIDS Cohort Study (MACS), Bethesda, NIH (USA)                  |
| 2001-2003 | Program leader, e-learning curriculum in public health, School of public health, Univ Bordeaux (France)  |
| 2003-2007 | Member, Inserm committee for the evaluation of researchers, research teams and units in public health ("CSS3") (France)  |
| 2004      | Member of grant review committee for the European Commission (FP6)   |
| 2004      | Contributor, STrengthening the Reporting of OBServational studies in Epidemiology (STROBE) initiative (coordinators: D Altman, M. Egger, S. Pocock, JP Vandembroucke, E von Elm)               |
| 2004-     | Chair, coordinated action on "HIV and viral hepatitis cohorts", National Agency for Research on AIDS and viral hepatitis (ANRS)  |
| 2005-2006 | Member, Review of Applications responding to Units for HIV/AIDS Clinical Trials Networks RFA AI-05-002, National Institutes of Health (USA)  |
| 2005-2011 | Member, Data and Safety Monitoring Committee of SPARTAC trial, Medical Research Council (UK)   |
| 2007      | Creation of the "conference francophone d'épidémiologie Clinique" (EPICLIN), Chair scientific committee in 2007 and 2014, Association des épidémiologistes de langue française (ADELF), Inserm |
| 2007-2012 | Member, experts for the national guidelines for case management of HIV infection, Ministry of Health (France)  |
| 2007-2013 | Member or Chair, evaluation committees for different Inserm research units or clinical investigation centers (France)  |
| 2007-2009 | Member, Scientific evaluation committee for the national program for clinical research ("PHRC"), Ministry of Health (France)   |
| 2007-2014 | <i>Plos One</i> Academic Editor  |
| 2007-2015 | Member, National committee for the evaluation of tenure positions at the Universities ("CNU"), "sous-section 4604" (Biostatistics and medical informatics) (France)                            |
| 2008-10   | Chair, Conseil Scientifique de la Fondation pour l'Innovation dans le domaine des Maladies Infectieuses (FINOVI), Université Lyon (France)   |
| 2012-     | Member, Advisory Board of the National Stichting HIV Monitoring, Amsterdam (Netherlands)   |
| 2010-2015 | Chair, National committee for the evaluation of tenure positions at the Universities ("CNU"), "sous-section 4604" (France)   |
| 2008-2013 | Member, scientific committee, EPICLIN conference   |
| 2009-2014 | Chair, Scientific secretariat, « International Workshop on HIV observational database », EuroCoord   |
| 2013-     | Vice-Chair, Scientific evaluation committee for the national program for clinical research ("PHRC"), Ministry of Health (France)   |
| 2014-     | Member, Editorial Board, Public Health reviews   |

Past Positions

|           |   |
|-----------|---|
| 1993-1994 | Visiting Research Fellow, London School of Hygiene and Tropical Medicine  |
| 1999-2013 | Head, Clinical epidemiology unit (« USMR »), Bordeaux University Hospital |
| 2003-2006 | Leader of the Inserm research team: "Clinical research" (Inserm U593)     |
| 2004-2007 | Deputy leader, CIC-EC7, Inserm-Bordeaux University Hospital               |

Professional Memberships

|              |  |
|--------------|--|
| 1999-present | Member, Collège des enseignants en biostatistique et informatique médicale, CIMES (France) |
| 2003-present | Member, International AIDS Society (USA)   |

Awards

|           |  |
|-----------|--|
| 1988      | Prix de Gérontologie, Union des Groupements d'Achat Public (UGAP) et Fondation Nationale de Gérontologie (FNG) |
| 2008-2011 | Prime d'Encadrement et de Recherche (PEDR)   |
| 2012-     | Prime d'excellence scientifique (PES)  |

Key bibliometric numbers

**Top 1% of most cited scientists in clinical medicine and immunology (Isi Web of Knowledge)**

**Publications: 350 - H factor: 53**

**Selection of papers:**

1. G. Chêne, P. Morlat, F. Dabis and the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Impact of revision of AIDS case definition [letter]. *Lancet* 1992; 339:1298-1299.

2. C. Leport, G. Chêne, P. Morlat, B.J. Luft, F. Rousseau, S. Pueyo, R. Hafner, J. Miro, J. Aubertin, R. Salamon, J-L. Vildé, and ANRS 005-ACTG 154 Group members. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. **Journal of Infectious Diseases** 1996; 173:91-7.
3. G. Chêne, S.G. Thompson. Methods for summarizing the risk associations of quantitative variables in epidemiological studies in a consistent form. **American Journal of Epidemiology** 1996;144:610-21.
4. G. Chêne, P.J. Easterbrook, E. Juszczak, Yu Ly Mee, SJ Pocock, BG Gazzard. Long-term survival in patients with advanced immunodeficiency. **AIDS** 1997;11:209-16.
5. G. Chêne, C. Binquet, JF. Moreau, D. Neau, I. Pellegrin, D. Malvy, J. Ceccaldi, D. Lacoste, F. Dabis and the Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA). Changes in CD4+ cell count and the risk of opportunistic infections or death after highly active antiretroviral treatment. **AIDS** 1998;12:2313-20.
6. X. Anglaret, G. Chêne, A. Attia, T. Siaka, S. Lafont, P. Combe, T. N'Dri-Yoman, R. Salamon, and the Cotrimo-CI study group. Early cotrimoxazole chemoprophylaxis for HIV-infected adults in Africa: A double blind placebo-controlled trial, ANRS 059. **Lancet** 1999;353:1463-8.
7. R. Thiébaud, P. Morlat, H. Jacqmin-Gadda, D. Neau, P. Mercié, F. Dabis, G. Chêne and the Groupe d'Epidémiologie Clinique du Sida en Aquitaine. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. **AIDS** 2000;14:971-8.
8. C. Binquet, G. Chêne, H. Jacqmin-Gadda, V. Journot, M. Savès, J-F. Moreau, D. Lacoste, F. Dabis and the Groupe d'Epidémiologie Clinique du Sida en Aquitaine. Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections. The Aquitaine Cohort, 1996-1997. **American Journal of Epidemiology** 2001;153:386-393.
9. M. Savès, F. Raffi, J. Capeau, W. Rozenbaum, J-M. Ragnaud, C. Perronne, A. Basdevant, C. Leport, G. Chêne and APROCO Study Group. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. **Clinical Infectious Diseases** 2002;34:1396-405.
10. M. Egger, M. May, G. Chêne, AN Phillips, B. Ledergerber, F. Dabis, D. Costagliola, A. D'Arminio Monforte, F. de Wolf, P. Reiss, JD. Lundgren, AC. Justice, S. Staszewski, C. Leport, RS. Hogg, CA. Sabin, MJ. Gill, B. Salzberger, JA. Sterne and ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. **Lancet** 2002;360:119-29.
11. M. Savès, G. Chêne, P. Ducimetière, C. Leport, G. Le Moal, P. Amouyel, D. Arveiler, J-B. Ruidavets, J. Reynes, A. Bingham, F. Raffi, the French WHO MONICA Project, the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. **Clinical Infectious Diseases** 2003;37:292-8.
12. G. Chêne, J. Sterne, M. May, D. Costagliola, B. Ledergerber, A. Phillips, F. Dabis, J. Lundgren, A. D'Arminio Monforte, F. de Wolf, R. Hogg, P. Reiss, A. Justice, C. Leport, S. Staszewski, J. Gill, G. Fatkenheuer, M. Egger. Prognostic significance of early immunologic and virologic response in HIV-1 infected patients starting potent antiretroviral therapy. **Lancet** 2003;362:676-686.
13. Y. Yazdanpanah, D. Sissoko, M. Egger, Y. Mouton, M. Zwahlen, G. Chêne. Clinical Efficacy of Antiretroviral Combination Therapy based on Protease or Non Nucleoside Analogue Reverse Transcriptase Inhibitors: Indirect Comparison of Controlled Trials. **British Medical Journal** 2004;328:249 (publication électronique d'un article original, accompagné d'un commentaire éditorial).
14. C. Lewden, D. Salmon, P. Morlat, S. Bévilacqua, E. Jouglà, F. Bonnet, L. Héripret, D. Costagliola, T. May, G. Chêne and the "Mortalité 2000" study group. Causes of death among human-immunodeficiency virus (HIV)-infected adults in the era of highly active antiretroviral therapy (HAART): the emerging role of hepatitis and cancers, the persistent role of AIDS. **International Journal of Epidemiology** 2005;34:121-30.
15. J-M. Molina, V. Journot, L. Morand-Joubert, P. Yéni, W. Rozenbaum, C. Rancinan, S. Fournier, P. Morlat, P. Palmer, B. Dupont, C. Goujard, P. Dellamonica, F. Collin, I. Poizot-Martin, G. Chêne for the ALIZE (ANRS 099) Study Team. Once-daily Emtricitabine, Didanosine and Efavirenz versus Protease Inhibitor-based Therapy in Patients with Human Immunodeficiency Virus Infection. **Journal of Infectious Diseases** 2005;191:830-839.
16. D. Salmon, C. Lewden, P. Morlat, S. Bévilacqua, E. Jouglà, F. Bonnet, L. Héripret, D. Costagliola, T. May, G. Chêne and the «Mortality 2000» study group. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B virus and alcohol. **Journal of Hepatology** 2005;42:799-805.
17. S. Matheron, F. Damond, A. Benard, A. Taieb, P. Campa, G. Peytavin, S. Pueyo, F. Brun-Vezinet, G. Chêne. CD4+ cell recovery in treated HIV2 infected adults is lower than expected: results from the French ANRS CO5 HIV2 cohort [Research Letter]. **AIDS** 2006; 20:459-62.

18. O Lortholary, G. Poizat, K. Sitbon, V. Zeller, S. Neuville, A. Boisbieux, M. Alvarez, F. Botterel, P. Dellamonica, F. Dromer, G. Chêne and the French Cryptococcosis Study Group. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. **AIDS** 2006;20:2183-2191.
19. SYROCOT Study Group: R. Thiébaud, S. Leproust, G. Chêne, R. Gilbert on behalf of the SYROCOT investigators. Individual patient data meta-analysis of prenatal treatment effect for congenital toxoplasmosis. **Lancet** 2007;369:115-22.
20. P. Lesprit, G Pédrone, J M Molina, C Goujard, P M Girard, N Sarrazin, C Katlama, P Yéni, P Morineau, J F Delfraissy, G Chêne\*, Y Lévy\* and ANRS 114-Pneumovac Study Group. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. **AIDS** 2007;21:2425-2434.  
\* contributed equally to this work
21. Collaboration of HIV Epidemiological Research Europe (COHERE) (writing group: Sabin C, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chêne G, Lundgren J). Response to combination antiretroviral therapy: variation by age. **AIDS** 2008;22:1463-73.
22. C. Lewden, T. May, E. Rosenthal, C. Burty, F. Bonnet, D. Costagliola, E. Jouglu, C. Semaille, P. Morlat, D. Salmon, P. Cacoub, G. Chêne and the ANRS EN19 Mortalité Study Group and Mortavic. Comparison of causes of death among adults infected by the Human Immunodeficiency Virus (HIV) between 2000 and 2005. **J AIDS** 2008;48:590-598.
23. D. Salmon, E. Rosenthal, C. Lewden, V. Bouteloup, T. May, C. Burty, F. Bonnet, D. Costagliola, E. Jouglu, C. Semaille, P. Morlat, P. Cacoub, G. Chêne, the ANRS EN19 Mortalité Study Group and Mortavic. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalité 2005 study. **Journal of Hepatology** 2009;50:736-45.
24. G. Pedrono, R. Thiébaud, A. Alioum, P. Lesprit, B. Fritzell, Y. Lévy, G. Chêne. A new endpoint formulation improved clinical relevance and statistical power in a vaccine trial. **Journal of Clinical Epidemiology** 2009;62:1054-61.
25. A. Bénard, F. Damond, P. Campa, G. Peytavin, D. Descamps, C. Lascoux-Combes, A. Taiéb, F. Simon, B. Autran, F. Brun-Vezinet, G. Chêne, S. Matheron, ANRS CO5 HIV2 Cohort Study Group. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naïve HIV-2-infected patients. **AIDS** 2009;23:1171-3.
26. B. Marin, R. Thiébaud, HC Bucher, V. Rondeau, D. Costagliola, M. Dorrucchi, O. Hamouda, M. Prins, AS. Walker, K. Porter, C. Sabin, G. Chêne, CASCADE Study Group. Specific non-AIDS related deaths and immunodeficiency in the era of combination antiretroviral therapy. The Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE), 1996-2006. **AIDS** 2009;23:1743-53.
27. M. Bruyand, R Thiébaud, S Lawson-Ayayi, P Joly, A.J Sasco, P Mercié, JL Pellegrin, D Neau, F Dabis, P Morlat, G Chêne, F Bonnet for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Role of Uncontrolled HIV RNA Level and Immunodeficiency in the Occurrence of Malignancy in HIV-Infected Patients during the Combination Antiretroviral Therapy Era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. **Clinical Infectious Diseases** 2009;49:1109-16.
28. Y Yazdanpanah, C Fagard, D Descamps, AM Taburet, C Colin, B. Roquebert, C Katlama, G Pialoux, C Jacomet, C Piketty, D Bollens, JM Molina, G Chêne and the ANRS 139 TRIO Trial Group. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir in multidrug-resistant treatment-experienced HIV-infected patients: Results of the ANRS 139 TRIO trial. **Clinical Infectious Diseases** 2009;49:1441-9.
29. C. Leport, F. Raffi, J. Rossert, L. Iordache, E. Lootvoet, G. Chêne and the ANRS CO8 Copilote study group. Long term evolution and determinants of renal function in HIV-infected patients who began receiving Combination antiretroviral therapy in 1997-1999. ANRS CO8 APROCO-COPILOTE. **Clinical Infectious Diseases** 2009;49:1950-4.
30. The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) (writing group: R. Lodwick, D. Costagliola, P. Reiss, C. Torti, R. Teira, M. Dorrucchi, B. Ledergerber, Mocroft A, Podzamczek D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, García F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warszawski J, Thorne C, Masip J, Pérez-Hoyos S, Pillay D, van Sighem A, Lo Caputo S, Günthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chêne G, Lundgren JD, Phillips AN). Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. **Archives of Internal Medicine** 2010;170:410-419.

31. L. Richert, P. Dehail, P. Mercie, FA. Dauchy, M. Bruyand, C. Greib, F. Dabis, F. Bonnet, G. Chêne for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). High frequency of poor locomotor performance in HIV-infected patients, ANRS CO3 aquitaine Cohort. **AIDS** 2011;25:797-805.
32. Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaud R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G; for the EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. **Lancet Infectious Diseases** 2011;11:363-71.
33. R. Thiébaud, S. Matheron, A. Taieb, F. Brun-Vezinet, G. Chêne, B. Autran; for the immunology group of the ANRS CO5 HIV-2 cohort. Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. **AIDS** 2011;25(6):865-7.
34. J. Bohlius, K. Schmidlin, F. Boue, G. Faetkenheuer, M. May, AM. Caro-Murillo, A. Mocroft, F. Bonnet, G. Clifford, V. Paparizos, JM Miro, N. Obel, M. Prins, G. Chêne, M. Egger. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. **Blood** 2011;117(23):6100-8.
35. Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), H. Castro, A. Judd, DM. Gibb, K. Butler, RK. Lodwick, A. van Sighem, JT. Ramos, J. Warszawski, C. Thorne, A. Noguera-Julian, N. Obel, D. Costagliola, PA. Tookey, C. Colin, J. Kjaer, J. Grarup, G. Chêne, A. Phillips. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. **Lancet** 2011;377:1580-7.
36. A. Benard, A. van Sighem, A. Taieb, E. Valadas, J. Ruelle, V. Soriano, A. Calmy, C. Balotta, F. Damond, F. Brun-Vezinet, G. Chêne, S. Matheron; the ACHIEV2E Collaboration Study Group. Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E Collaboration Study Group. **Clinical Infectious Diseases** 2011;52:1257-1266.
37. The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group (Analysis and writing group: Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczak D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Pérez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A). Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. **Lancet Infectious Diseases** 2012;12(2):119-27.
38. J. Capeau, V. Bouteloup, C. Katlama, J-P. Bastard, V. Guiyedi, D. Salmon-Ceron, C. Protopopescu, C. Leport, F. Raffi, G. Chêne; the ANRS CO8 APROCO-COPILOTE Cohort Study Group. Ten-year diabetes incidence in 1,046 HIV-infected patients started on a combination antiretroviral treatment: the ANRS CO8 APROCO-COPILOTE cohort. **AIDS** 2012;26(3):303-14.
39. Y. Lévy, R. Thiébaud, M-L. Gougeon, J-M. Molina, L. Weiss, P-M. Girard, A. Venet, P. Morlat, B. Poirier, A-S. Lascaux, C. Boucherie, D. Sereni, C. Rouzioux, J-P. Viard, C. Lane, J-F. Delfraissy, I. Sereti, G. Chêne and the ILIAD Study Group. Effect of Intermittent Interleukin-2 Therapy on CD4+ T cell counts following antiretroviral cessation in patients with HIV (ANRS 118/NIH 04-I-0018 ILIAD Trial). **AIDS** 2012;26(6):711-720.
40. The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord (J Young, M Psychogiou, L Meyer, S Ayayi, S Grabar, F Raffi, P Reiss, B Gazzard, M Sharland, F Gutierrez, N Obel, O Kirk, JM Miro, HJ Furrer, A Castagna, S de Wit, J Munoz, J Kjaer, C Colin, J Grarup, G Chêne, H Bucher). CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. **Plos Medicine** 2012;9(3):e1001194.
41. C. Lewden, V. Bouteloup, S. De Wit, C. Sabin, A. Mocroft, JC. Wasmuth, A. van Sighem, O. Kirk, N. Obel, G. Panos, J. Ghosn, F. Dabis, M. Mary-Krause, C. Leport, S. Perez Hoyos, P. Sobrino-Vegas, C. Stephan, A. Castagna, A. Antinori, A. d'Arminio Monforte, C. Torti, C. Mussini, V. Isern, A. Calmy, R. Teira, M. Egger, J. Grarup, G. Chêne and COHERE in EuroCoord. All-cause mortality in HIV-infected adults with CD4  $\geq$ 500 /mm<sup>3</sup> compared to general population in a large European observational cohort collaboration. **International Journal of Epidemiology** 2012;41(2):433-45.
42. C. Goujard, D. Emilie, C. Roussillon, Véronique Godot, Christine Rouzioux, Alain Venet, Céline Colin, J.M. Livrozet, Daniel Sérén, P. Galanaud, G. Chêne, for the ANRS INTERPRIM Study Group. Virological effects

- of continuous versus intermittent antiviral therapy during primary HIV-1 infection: the INTERPRIM Trial. *AIDS* 2012;26(15):1895-905.
43. MM Glymour, G. Chêne, C Tzourio, C Dufouil. Brain MRI Markers and Dropout in a Longitudinal Study of Cognitive Aging: the 3-City Dijon Study. *Neurology* 2012;79(13):1340-8.
  44. F Bonnet, H Amieva, F Marquant, C Bernard, M Bruyand, FA Dauchy, P Mercié, C Greib, L Richert, D Neau, P Dehail, G Catheline, F Dabis, P Morlat, JF Dartigues, G Chêne for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Cognitive disorders in HIV-infected patients: are they HIV-related? ANRS CO3 Aquitaine Cohort, Bordeaux, France, 2007-2009. *AIDS* 2013;27(3):391-400.
  45. B. Ledergerber, D. Costagliola D, R. Lodwick, C. Torti, A. van Sighem, D. Podzamczar, A. Mocroft, M. Dorrucchi, B. Masquelier, HF. Günthard, A. de Luca, C. Michalik, S. De Wit, N. Obel, G. Fätkenheuer, G. Chrysos, C. Mussini, A. Castagna, C. Stephan, F. García, R. Zangerle, X. Duval, S. Perez-Hoyos, L. Meyer, J. Ghosn, C. Fabre-Colin, J. Kjaer, J. Grarup, G. Chêne, A. Phillips A. Predictors of CD4 cell counts of HIV-1 -infected persons after virologic failure to all three original antiretroviral drug classes. *Journal of Infectious Diseases* 2013;207(5):759-67.
  46. Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD; for the Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. The Incidence of AIDS-Defining Illnesses at a Current CD4 Count  $\geq$ 200 Cells/ $\mu$ L in the Post-Combination Antiretroviral Therapy Era. *Clinical Infectious Diseases* 2013;57(7):1038-47.
  47. Mocroft A, Lundgren JD, Sabin ML, Monforte AD, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S, Fätkenheuer G, Furrer H, Johnson AM, Lazanas MK, Leport C, Moreno S, Obel N, Post FA, Reekie J, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Lozano I, Torti C, Warszawski J, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Kirk O; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). *Plos Medicine* 2013;10(9):e1001510.
  48. Richert L, Brault M, Mercié P, Dauchy FA, Bruyand M, Greib C, Dabis F, Bonnet F, Chêne G, Dehail P; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Handgrip Strength Is Only Weakly Correlated With Physical Function in Well-Controlled HIV Infection: ANRS CO3 Aquitaine Cohort. *Journal of Acquired Immune Deficiency Syndrome* 2014;65(1):e25-7.
  49. Richert L, Brault M, Mercié P, Dauchy FA, Bruyand M, Greib C, Dabis F, Bonnet F, Chêne G, Dehail P; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Decline in locomotor functions over time in HIV-infected patients. *AIDS* 2014;28(10):1441-9.
  50. Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, Brites C, Madruga JV, Barcellos NT, Santos BR, Vorsatz C, Fagard C, Santini-Oliveira M, Patey O, Delaugerre C, Chêne G, Molina JM; ANRS 12 180 Reflate TB study group. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. *Lancet Infectious Diseases* 2014;14(6):459-67.
  51. Dufouil C, Pereira E, Chêne G, Glymour MM, Alperovitch A, Saubusse E, Risse-Fleury M, Heuls B, Salord JC, Brieu MA, Forette F. Older age at retirement is associated with decreased risk of dementia. *European Journal of Epidemiology* 2014;29(5):353-61.
  52. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, Georget A, Aouba A, Rosenthal E, May T, Chauveau M, Diallo B, Costagliola D, Chêne G; ANRS EN20 Mortalité 2010 Study Group. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. *AIDS* 2014;28(8):1181-91.
  53. Natural History Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord: F. Nakagawa, R. Lodwick, C. Smith, D. Costagliola, A. van Sighem, B. Ledergerber, A. d'Arminio Monforte, M. Dorrucchi, C. Torti, I. Suarez-Lozano, N. Obel, N. Brockmeyer, R. Thiebaut, J. Lundgren, A. Castagna, B. Alejos, S. De Wit, R. Zangerle, N. Pantazis, K. Ehren, J. Casabona, J. Grarup, G. Chêne, A. Phillips. Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naïve individuals. *AIDS* 2014;28(9):1351-6.
  54. Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or

- tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. **Lancet** 2014;384(9958):1942-51.
55. Dufouil C, Seshadri S, Chêne G. Cardiovascular risk profile in women and dementia. **Journal of Alzheimer's Disease** 2014;42 Suppl 4:S353-63.
  56. Chêne G, Beiser A, Au R, Preis SR, Wolf PA, Dufouil C, Seshadri S. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. **Alzheimer & Dementia** 2015;11(3):310-20.
  57. C. Dufouil, L. Richert, R. Thiebaut, M. Bruyant, H. Amieva, F. Dauchy, J-F. Dartigues, D. Neau, P. Morlat, P. Dehail, F. Dabis, F. Bonnet, G. Chêne. Diabetes and cognitive decline in a French cohort of HIV-1 infected patients. **Neurology** 2015 (in press)
  58. A. Vivot, M. Glymour, C. Tzourio, P. Amouyel, G. Chêne, C. Dufouil. Association of Alzheimer's Related Genotypes with Cognitive Decline in Multiple Domains: Results from the Three City-Dijon Study. **Molecular Psychiatry** 2015 (in press)

#### Invited seminars (2010 - 2015)

- 38ème Congrès de la Société de Réanimation de Langue Française, Paris, France : (Pourquoi) Les méta-analyses des études de l'efficacité des corticoïdes sur le sepsis grave de l'adulte donnent-elles des résultats contradictoires ? Janvier 2010.
- European AIDS Treatment Group, Annual Assembly, Francfort, Allemagne: NEAT Session. Management of clinical trials in Europe: the example of HIV/AIDS, the case of NEAT 001/ANRS 143. What does it take to manage a clinical trial in Europe? Mai 2010.
- Collège de France, Paris, France. Quel est l'avenir de l'épidémie de sida ? (en hommage au Pr Peter Piot) Les enjeux futurs à travers les cohortes de patients. Septembre 2010.
- 8ème Réunion Annuelle Laboratoires et CROs Essais Cliniques 2010, Paris, France : Sélectionner les indicateurs clés de mesure de la performance de vos essais cliniques. Revue de tous les postes de coûts de la chaîne. Septembre 2010.
- XXVIèmes Rencontres Nationales de Pharmacologie Clinique, Atelier « cohortes », Giens, France : Cohorte Memento. Octobre 2010.
- XVIe Assises & XIe Congrès de la Société Française de Lutte contre le Sida, Atelier « Recherche Clinique : points de vue croisés », Bordeaux, France : avis méthodologique. Novembre 2010.
- Ministère de l'Enseignement supérieur et de la recherche, Conférence de chercheurs sur l'actualité sur les recherches sur le sida, Paris, France : Cohortes: les enjeux nationaux et européens. Novembre 2010.
- Assises Hospitalo Universitaires, Lyon, France : Trois retours d'expérience sur les CRBSP : quelle contribution stratégique ? Décembre 2010.
- Soirée 2011 de la Recherche clinique, Bordeaux, France : le CHU, promoteur national de la cohorte Alzheimer Memento. Juin 2011
- International AIDS Conference, ANRS Satellite symposium "HIV2: a model of attenuated infection", Roma, Italy: ACHIEV2E, COHERE & EuroCoord: Added value of collaborative studies, July 2011.
- AVIESAN, Journée Recherche et Santé « Franchir le pas vers la recherche clinique », Paris, France: Recherche clinique : (un peu de) méthodes pour garantir la validité des résultats, Janvier 2012.
- 11ème Réunion Francophone sur la Maladie d'Alzheimer et les syndromes apparentés, Toulouse, France: Biomarqueurs du VIH/sida : échecs, succès et perspectives. Mai 2012
- Université Bordeaux Segalen, Ecole d'Été de l'Institut de Santé Publique, d'Epidémiologie et de Développement (Isped), Bordeaux, France: Recherche translationnelle : les épidémiologistes sont-ils incontournables ? Juin 2012.
- Harvard School of Public Health, Department of Society, Human Development and Health Seminar Series, Boston, United States: Translational epidemiology: are we ready for a population perspective in our research? September 2012.
- AVIESAN-Inserm, 20 ans des CIC, Paris, France : Contributions à l'implémentation des cohortes dans un environnement clinique (exemples : sida et maladie d'Alzheimer). Octobre 2012.
- Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS), 25 ans de l'ANRS, Paris, France : Quelles sont les grandes avancées en recherche fondamentale, clinique, épidémiologie, santé publique, vaccinale et dans les pays du Sud, auxquelles l'ANRS a participé depuis 25 ans dans le domaine du VIH ? Interview filmée avec 5 autres chercheurs. Novembre 2013
- Agence Régionale de Santé d'Aquitaine, Débat régional d'Aquitaine sur la Stratégie Nationale de Santé, Pessac, France. Participation au débat comme « grand témoin ». Janvier 2014.
- Ministère des affaires sociales et de la santé, présentation des orientations de la loi de santé par la ministre des affaires sociales et de la santé et par la secrétaire d'état à l'enseignement supérieur et à la recherche, Paris, France. Intervention sur les indicateurs de santé et la recherche en santé publique, Juin 2014.
- Conférence des Présidents d'Université, Colloque Santé Publique, Paris, France. La simplification du paysage dans sa structuration. Session « La recherche et l'innovation en santé », Juin 2014.

World Health Summit, Berlin, Berlin, Allemagne. Panel discussion on Translational Medicine: What is Translation in Medicine and How to Promote It? Different Models in Different Countries. The case of Inserm, Octobre 2014.

Other invitations

1. Habilitations: 14 as external examiner or president.
2. PhD: 16 as external examiner, 11 as supervisor.
3. Report for the nomination of professors, University College London: 2

Major Ongoing Research Supports

|  |  |                                    |
|--|--|------------------------------------|
| 2011-2015  | FP7/Contrat n°260694                   | Chêne G (beneficiary, WP leader)   |
| EuroCoord: European Network of HIV/AIDS Cohort Studies to Coordinate at European and International Level Clinical Research on HIV/AIDS |  |                                    |
| Amount: 1,050,000 euros.   |  |                                    |
|  |  |                                    |
| 2011-2015  | Fondation Plan Alzheimer               | Chêne, Bordeaux Univ Hospital (PI) |
| Alzheimer methodology group and Memento cohort.  |  |                                    |
| Amount: 2,400,000 euros.   |  |                                    |
|  |  |                                    |
| 2014-2018  | F-CRIN/ANR                             | Chêne (PI) & Richert (co-PI)       |
| Clinical epidemiology platform for trials – “EUCLID”   |  |                                    |
| Amount: 2,050,000 euros.   |  |                                    |
|  |  |                                    |
| 2015   | Ministry of Health and Inserm (France) | Chêne G (PI)                       |
| Annual recurrent funding.  |  |                                    |
| Amount: 230,000 euros.   |  |                                    |
|  |  |                                    |
| 2015   | ANRS                                   | Chêne G (PI)                       |
| Clinical Trials Unit and clinical epidemiology research activities. Annual funding.  |  |                                    |
| Amount: 2,500,000.   |  |                                    |